<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-717
Date of Submission: 2025-02-08

This report was submitted by a Pharmacist from Warner-Conley Medical Center concerning patient ANON-PX-2976. The subject is an adult female with a significant medical history including chronic kidney disease, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin administered via the Topical route at a dosage of 253mg, initiated on 2024-11-27 for Neuropathic pain and discontinued on 2025-01-15; Omeprazole administered via the Subcutaneous route at a dosage of 227mg, initiated on 2024-11-27 for Gastroesophageal reflux disease and discontinued on 2025-01-15.

On approximately 2025-01-01, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Pruritus. The Diarrhea was classified as Severe in severity. This necessitated clinical intervention. The documented action was: Prescribed life and advised concern. The current patient status regarding this symptom is 'Recovered'. The Pruritus was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 6 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Negative dechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Toward prevent form school call. Issue rule girl person important five region parent. Nice boy under go store set.</data>
report_id: ADR-2025-717
report_date: '2025-02-08'
patient_details:
  patient_id: ANON-PX-2976
  gender: Female
  relevant_history:
  - chronic kidney disease
  - migraines
suspected_drugs:
- drug_name: Gabapentin
  dosage: 253mg
  route_of_administration: Topical
  start_date: '2024-11-27'
  indication_for_use: Neuropathic pain
  end_date: '2025-01-15'
- drug_name: Omeprazole
  dosage: 227mg
  route_of_administration: Subcutaneous
  start_date: '2024-11-27'
  indication_for_use: Gastroesophageal reflux disease
  end_date: '2025-01-15'
adverse_reactions:
- symptom_name: Diarrhea
  onset_date: '2025-01-01'
  severity: Severe
  outcome: Recovered
  intervention_required: true
  intervention_details: Prescribed life and advised concern.
- symptom_name: Pruritus
  onset_date: '2025-01-01'
  severity: Moderate
  outcome: Fatal
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Negative dechallenge
  naranjo_score: 6
reporting_facility: Warner-Conley Medical Center
reporter_type: Pharmacist
notes: Toward prevent form school call. Issue rule girl person important five region
  parent. Nice boy under go store set.
